BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26438014)

  • 1. Meta-analysis comparing doublet and single cytotoxic agent therapy as first-line treatment in elderly patients with advanced nonsmall-cell lung cancer.
    Wang S; Wang Q; Tian J; Zhou Z; Jiao L; Fu Y; Chen S; Zhang J; Xu L
    J Int Med Res; 2015 Dec; 43(6):727-37. PubMed ID: 26438014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
    Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; de Castria TB; Cruz MR; Riera R
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010463. PubMed ID: 26482542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for advanced non-small cell lung cancer in the elderly population.
    Santos FN; Castria TB; Cruz MR; Riera R
    Sao Paulo Med J; 2016; 134(5):465-466. PubMed ID: 27901246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis.
    Des Guetz G; Uzzan B; Nicolas P; Valeyre D; Sebbane G; Morere JF
    Crit Rev Oncol Hematol; 2012 Dec; 84(3):340-9. PubMed ID: 22534083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials.
    Xu CA; Chang ZY; Wang XJ; Qi HY
    Int J Clin Pract; 2013 Nov; 67(11):1118-27. PubMed ID: 24165426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: a meta-analysis.
    Luo L; Hu Q; Jiang JX; Yang X; Dinglin XX; Lin X; Yao HR
    Asia Pac J Clin Oncol; 2015 Sep; 11(3):253-61. PubMed ID: 25866140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
    Pan G; Ke S; Zhao J
    Target Oncol; 2013 Jun; 8(2):107-16. PubMed ID: 23516098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Best first-line therapy for people with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status.
    Gijtenbeek RG; de Jong K; Venmans BJ; van Vollenhoven FH; Ten Brinke A; Van der Wekken AJ; van Geffen WH
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD013382. PubMed ID: 37419867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
    Rajeswaran A; Trojan A; Burnand B; Giannelli M
    Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis.
    Zhong A; Xiong X; Shi M; Xu H
    Drug Des Devel Ther; 2015; 9():3685-93. PubMed ID: 26229433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis.
    Guo X; Zhao F; Ma X; Shen G; Ren D; Zheng F; Du F; Wang Z; Ahmad R; Yuan X; Zhao J; Zhao J
    BMC Cancer; 2019 Nov; 19(1):1125. PubMed ID: 31747911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
    Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
    Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
    Sun L; Ma JT; Zhang SL; Zou HW; Han CB
    Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A meta analysis of doublets versus single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer].
    Xu C; Chang Z; Wang X; Li L; Qi H; Liu Y
    Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):361-8. PubMed ID: 22681923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aidi injection plus platinum-based chemotherapy for stage IIIB/IV non-small cell lung cancer: A meta-analysis of 42 RCTs following the PRISMA guidelines.
    Wang J; Li G; Yu L; Mo T; Wu Q; Zhou Z
    J Ethnopharmacol; 2018 Jul; 221():137-150. PubMed ID: 29655852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.
    Delbaldo C; Michiels S; Syz N; Soria JC; Le Chevalier T; Pignon JP
    JAMA; 2004 Jul; 292(4):470-84. PubMed ID: 15280345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.